195 related articles for article (PubMed ID: 27449070)
1. Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer.
Fernández-López C; Expósito-Hernández J; Arrebola-Moreno JP; Calleja-Hernández MÁ; Expósito-Ruíz M; Guerrero-Tejada R; Linares I; Cabeza-Barrera J
Cancer Med; 2016 Sep; 5(9):2190-7. PubMed ID: 27449070
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.
Brundage MD; Mackillop WJ
J Clin Epidemiol; 1996 Feb; 49(2):183-92. PubMed ID: 8606319
[TBL] [Abstract][Full Text] [Related]
3. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Langer F; Helsberg K; Schütte WH; Leschinger MI
Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
[TBL] [Abstract][Full Text] [Related]
4. Trends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study.
Fernández-López C; Calleja-Hernández MÁ; Balbino JE; Cabeza-Barrera J; Expósito-Hernández J
Thorac Cancer; 2019 Apr; 10(4):904-908. PubMed ID: 30868737
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Buffoni L; Vavalà T; Novello S
Curr Treat Options Oncol; 2016 Oct; 17(10):54. PubMed ID: 27523606
[TBL] [Abstract][Full Text] [Related]
7. Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.
Ghimire S; Kyung E; Kim E
Lung; 2013 Aug; 191(4):313-9. PubMed ID: 23715997
[TBL] [Abstract][Full Text] [Related]
8. Combined modality therapy of non-small cell lung cancers.
Juretic A; Sobat H; Samija M
Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
Tsuchiya T; Matsumoto K; Miyazaki T; Doi R; Tokunaga S; Yamaguchi H; Tomoshige K; Watanabe H; Nagayasu T; Sugio K
BMC Cancer; 2021 Mar; 21(1):249. PubMed ID: 33685421
[TBL] [Abstract][Full Text] [Related]
10. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies.
Choy H; Gerber DE; Bradley JD; Iyengar P; Monberg M; Treat J; Govindan R; Koustensis A; Barker S; Obasaju C
Lung Cancer; 2015 Mar; 87(3):232-40. PubMed ID: 25650301
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
12. Oligometastatic non-small cell lung cancer: Where do we go next?
Malik N; Palma D
Lung Cancer; 2017 Apr; 106():145-147. PubMed ID: 28062090
[No Abstract] [Full Text] [Related]
13. Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
Capelan M; Roda D; Geuna E; Rihawi K; Bodla S; Kaye SB; Bhosle J; Banerji U; O'Brien M; de Bono JS; Popat S; Yap TA
Lung Cancer; 2017 Sep; 111():6-11. PubMed ID: 28838399
[TBL] [Abstract][Full Text] [Related]
14. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
15. Combined modality therapy of early stage nonsmall cell lung cancer.
Pisters KM
Respir Care Clin N Am; 2003 Jun; 9(2):191-205. PubMed ID: 12911289
[TBL] [Abstract][Full Text] [Related]
16. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
[TBL] [Abstract][Full Text] [Related]
17. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC.
Halvorsen TO; Stokke K; Killingberg KT; Raj SX; Sørhaug S; Brustugun OT; Fløtten Ø; Helbekkmo N; Hornslien K; Madebo T; Fluge S; Grønberg BH
Acta Oncol; 2020 Sep; 59(9):1051-1057. PubMed ID: 32543258
[No Abstract] [Full Text] [Related]
20. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Custodio A; de Castro J
Crit Rev Oncol Hematol; 2012 Jun; 82(3):338-60. PubMed ID: 21908201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
